NHS offers Dostarlimab (Jemperli) to advanced womb cancer patients, extending life expectancy with chemotherapy.

New cancer treatment Dostarlimab, sold under the brand name Jemperli, is now available on NHS for women with advanced or recurring womb cancer. Approved by the National Institute for Health and Care Excellence (Nice), the immunotherapy drug extends life expectancy when used with chemotherapy. Up to 200 patients will benefit each year, with the treatment expected to provide "precious extra time" with loved ones.

March 05, 2024
4 Articles